Table 1. Characteristics of studies included in the meta-analysis.
| First author | Year | Country | Case | Cancer type | Detection | Provided information on cutoff value | Outcome endpoints | NOS score |
|---|---|---|---|---|---|---|---|---|
| Tsai MM [18] | 2016 | Taiwan | 77 | gastric cancer | IHC | score ≥ 40 | OS | 9 |
| Zhang Y [12] | 2015 | China | 195 | colon cancer | IHC | score ≥3(range of 0-7) | OS,DFS | 8 |
| Takada T [13] | 2015 | Japan | 135 | colorectal cancer | IHC | Low = score 0-4; high = score 6, 9 | OS | 8 |
| Alshareeda AT [14] | 2015 | UK | 1494 | breast cancer | IHC | negative/low<35, positive≥35H-score(range of 0-300) | OS | 9 |
| Shi B [29] | 2015 | China | 176 | upper tract urothelial carcinoma | IHC | strong nuclear staining in at least 10% | OS,DFS | 9 |
| Erben PB [22] | 2015 | Germany | 225 | head and neck squamous cell cancer | IHC | the percentage of positive stained nuclei >15%(median) | DFS | 8 |
| Hu ZY [20] | 2014 | China | 314 | hepatocellular carcinoma | IHC | nucleus staining in more than 5% cells | OS,RFS | 7 |
| Jiang P [21] | 2014 | China | 221 | hepatocellular carcinoma | IHC | extent≥5% (range from 0 to 100%) | OS,TTR | 9 |
| Gousias K [24] | 2014 | Germany | 108 | meningiomas | IHC | the percentage of moderately or strongly immunopositive cell nuclei ≥5% (median) | PFS | 9 |
| Ikenberg K [26] | 2014 | Switzerland | 527 | endometrial cancer | IHC | strong nuclear staining in at least 10% of nuclei | OS | 9 |
| Huang L [4] | 2013 | China | 191 | epithelial ovarian carcinoma | qRT-PCR | expression level of KPNA2>3.52 | OS.RFS | 8 |
| Altan B [19] | 2013 | Japan | 179 | gastric cancer | IHC | Low = score 0-3; high = score 4, 6, 9 | OS | 9 |
| Rachidi SM [11] | 2013 | USA | 54 | colon cancer | IHC | nuclear staining intensity score > 3 | OS | 8 |
| Li C [10] | 2013 | China | 142 | gastric cancer | IHC | score ≥ 4(range of 0-9) | OS | 8 |
| He L [25] | 2012 | China | 90 | ovarian malignant germ cell tumor | IHC | score ≥ 2.5(range of 0-12) | OS,DFS | 7 |
| Gousias K (a) [23]# | 2012 | Germany | 94 | Astrocytomas | IHC | ≥5% nuclear immunoreactivity | OS,PFS | 9 |
| Gousias K (b) [23]# | 2012 | Germany | 47 | Glioblastomas | IHC | ≥10% nuclear immunoreactivity | OS,PFS | 9 |
| Mortezavi A (a) [8]# | 2011 | Switzerland | 341 | prostate cancer | IHC | Nuclear KPNA2 immunoreactivity>0% | RFS | 9 |
| Mortezavi A (b) [8]# | 2011 | Switzerland | 237 | prostate cancer | IHC | Nuclear KPNA2 immunoreactivity>0% | RFS | 9 |
| Jensen JB [27] | 2011 | Denmark | 377 | bladder cancer | IHC | nuclear staining of ≥10% of the carcinoma cells | OS,RFS | 8 |
| Zheng M [31] | 2010 | China | 102 | epithelial ovarian carcinoma | IHC | scores of (++) and (+++) were recorded as positive | OS | 9 |
| Sakai M [28] | 2010 | Japan | 116 | Esophageal Squamous Cell Carcinoma | IHC | KPNA2 LI(labeling index) ≥10.7%(range 0-44.3%) | OS | 8 |
| Gluz O [15] | 2008 | Germany | 191 | breast cancer | IHC | nuclear expression >10% of nuclei | OS | 8 |
| Dankof A [16] | 2007 | Germany | 83 | breast cancer | IHC | nuclear expression >10% of nuclei | DFS | 9 |
| Dahl E [17] | 2006 | Germany | 272 | breast cancer | IHC | nuclear expression≥10% of nuclei | OS | 9 |
| Winnepenninckx V [30] | 2006 | Belgium | 176 | melanoma | IHC | >average expression value | OS | 9 |
IHC : Immunohistochemistry; qRT-PCR:Quantitative Real Time Polymerase Chain Reaction;NOS: Newcastle-Ottawa Scale; DFS: disease free survival; TTR: time to recurrence ; RFS: recurrence free survival; PFS: progression free survival.
#
There were two parts of data(a and b)in each of the studies of Gousias K and Mortezavi A.